BioCryst Stock Jumps After Hours On Big Pharma Suitor Buzz — Retail Sentiment Hits 2026 Peak

• Retail traders debated the timing and pricing of the buyout, with some expecting an all-cash offer and others speculating about various takeover scenarios.
• Skeptical users noted BioCryst’s history as an acquirer and argued shares would likely trade closer to $14-$15 if firm deal insights existed.
• The company's growth remains anchored by Orladeyo, which generated $601 million in revenue and $214 million in non-GAAP operating profit last year.

Shares of BioCryst Pharmaceuticals, Inc. (BCRX) jumped about 11% in after-hours trading on Monday as retail sentiment hit its strongest level of 2026 and volumes doubled, fueling speculation that a U.S. biopharma worth over $15 billion could be circling the company.

BCRX stock ended over 1% higher at $9.8 on Monday, with shares up 23% over the past year.

Retail Investors Weigh Buyout Odds For BCRX

The renewed takeover buzz followed last week's reports of a Betaville “uncooked” alert, which said that a party interested in BioCryst may be a U.S.-based biopharma firm with a market cap exceeding $15 billion. Among the biotech companies with a market cap between $15 billion and $20 billion are Incyte Corp., Revolution Medicines, Inc., Roivant Sciences Ltd., and Exact Sciences Corp.

On Stocktwits, retail sentiment for BCRX has remained ‘extremely bullish’ over the past three months and recently climbed to its strongest level of 2026 amid nearly a 300% surge in message volumes, with investors debating whether the after-hours rally reflected positioning ahead of a potential acquisition.

One trader said, “Somebody knows something. A $10 stock doesn’t just go up 10%+ for nothing after hours.” Meanwhile, another trader expects a buyout to be announced as soon as Wednesday, in an all-cash offer.

Some observers suggested institutional positioning at lower levels supported the takeover narrative, arguing that entry around $9.7 signaled confidence in further upside and the possibility that larger pharmaceutical companies could emerge as bidders.

Others framed possible price scenarios depending on whether a deal materializes, estimating the shares could reach $16-$18 in a buyout case, trade toward $13-$16 with continued execution, or fall toward $7-$9 if competition increases, with further downside possible if pipeline expectations weaken. 

However, not all views supported the takeover thesis. One user noted that the company’s history suggested it may prefer acting as an acquirer rather than a target, while another argued that if investors had firm takeover insight, the stock would already be trading closer to $14-$15. 

“If the BO [buyout] speculation (if that even is what is happening) goes away, this certainly could drop back,” said one user. “But I would just like to point out that even at these levels, this is not even trading at 4x current revs. So it is certainly not overvalued here with or without BO rumors.”

Orladeyo Anchors Growth Outlook

The takeover speculation surfaced alongside improving pipeline visibility, highlighted earlier this month at the TD Cowen 46th Annual Health Care Conference. CEO Charlie Gayer said the company generated $601 million in revenue last year from Orladeyo, its oral preventive treatment for hereditary angioedema, and $214 million in non-GAAP operating profit.

“Orladeyo is still the most differentiated product on the market because it’s the only oral prophylactic on the market today,” Gayer said, adding that half of the patients starting Orladeyo are switching from injectable prophylaxis therapies.

The company also highlighted Navenibart, the late-stage hereditary angioedema therapy acquired with Astria, as a key driver of future franchise expansion. It also noted that the composition-of-matter patent protection for Orladeyo extends to 2040.

Gayer added that the broader portfolio outlook remains strong: “We’re talking about a portfolio that we see growing at mid-teens in revenue well into the 2030s.”

For updates and corrections, email newsroom[at]stocktwits[dot]com.